As such, we were unable to study the proteomic effects of other recurrent mutations, such as lesions affecting NOTCH1 and SF3B1, although in other screens, their effects on global protein expression were found to be minimal.22,26 Second, as biobank participation terminated upon treatment initiation, the effects of protein expression on treatment efficacy and OS could not be evaluated in this CLL biobank cohort. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.